Paliperidone Palmitate

Dosage for paliperidone palmitate must be individualized based on the patient's clinical response and tolerability. For the monthly formulation (Invega Sustenna) in the treatment of schizophrenia or schizoaffective disorder, the standard initiation regimen for adults is:

• Day 1: 234 mg administered intramuscularly in the deltoid (shoulder) muscle.
• Day 8: 156 mg administered intramuscularly in the deltoid muscle.
• Maintenance Dose: Following initiation, the recommended monthly maintenance dose is 117 mg, though doses may range from 39 mg to 234 mg based on individual patient needs. Maintenance injections can be administered in either the deltoid or gluteal (buttock) muscle.

For the 3-month formulation (Invega Trinza), the dose is based on the previous monthly dose. For example, if a patient was stable on 117 mg monthly, the 3-month dose would be 410 mg. If they were on 234 mg monthly, the 3-month dose would be 819 mg. Similarly, the 6-month formulation (Invega Hafyera) doses are scaled up from the 3-month or monthly doses (e.g., 1,092 mg or 1,560 mg every six months).

Paliperidone palmitate is generally not approved for use in pediatric patients under the age of 18 for schizoaffective disorder. For schizophrenia, safety and effectiveness in adolescents have not been as extensively established for the long-acting injectable forms as they have for the oral formulation. Healthcare providers typically weigh the risks and benefits carefully before prescribing this to minors. Always follow the specific guidance of a pediatric psychiatrist.

Renal Impairment

Because paliperidone is primarily excreted by the kidneys, dosage adjustments are critical for patients with impaired renal function.

• Mild Renal Impairment (CrCl 50 to <80 mL/min): The initiation dose is typically reduced (e.g., 156 mg on Day 1 and 117 mg on Day 8), and the maintenance dose is adjusted to 78 mg monthly.
• Moderate to Severe Renal Impairment (CrCl <50 mL/min): Paliperidone palmitate is generally not recommended for patients with moderate or severe renal impairment, as appropriate dose reductions for these patients have not been established for the injectable formulation.

Hepatic Impairment

No dosage adjustment is typically required for patients with mild to moderate hepatic (liver) impairment (Child-Pugh Class A and B). Paliperidone has not been studied in patients with severe hepatic impairment, and caution is advised in this population.

Elderly Patients

In general, recommended dosing for elderly patients with normal renal function is the same as for younger adults. However, because elderly patients are more likely to have decreased renal function, healthcare providers often monitor kidney function closely and adjust the dose accordingly. There is also a heightened risk of side effects like orthostatic hypotension in this group.

Paliperidone palmitate must be administered by a healthcare professional. It is given as a deep intramuscular injection.

• Site of Injection: The initiation doses (Day 1 and 8) must be given in the deltoid muscle to reach therapeutic levels more quickly. Maintenance doses can be given in either the deltoid or the gluteal muscle.
• Preparation: The syringe must be shaken vigorously for at least 15 seconds with the tip pointing up to ensure a uniform suspension before administration.
• Food: Unlike the oral version of paliperidone, the absorption of the injectable form is not affected by food intake.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F). Do not freeze.

Missing a dose of a long-acting injectable can lead to a return of symptoms. If a dose is missed:

• Short Delay (less than 4 weeks since last monthly dose): The dose should be administered as soon as possible.
• Long Delay (4 to 6 weeks since last monthly dose): A specific re-initiation regimen may be required, involving deltoid injections.
• Extended Delay (more than 6 months): The full initiation schedule (Day 1 and Day 8) typically must be restarted.

Because the medication is administered by a healthcare professional, the risk of accidental overdose is low. However, signs of overdose may include severe extrapyramidal symptoms (uncontrolled muscle movements), extreme drowsiness, rapid heartbeat, or low blood pressure. In case of suspected overdose, emergency medical services should be contacted immediately. Treatment is supportive and focuses on maintaining an airway and monitoring cardiac function.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Common side effects of paliperidone palmitate are often manageable but can be distressing for patients. According to clinical trial data, these include:

• Injection Site Reactions: Pain, swelling, or redness at the site where the needle entered the muscle. This usually subsides within a few days.
• Somnolence (Drowsiness): A feeling of strong desire to sleep or unusually long periods of sleep. This is most common during the first few weeks of treatment.
• Weight Gain: Significant increases in body weight are common with atypical antipsychotics. This is often due to increased appetite and metabolic changes.
• Extrapyramidal Symptoms (EPS): These include tremors, restlessness (akathisia), muscle stiffness, or slow movements. Patients may feel like they 'cannot sit still.'

• Tachycardia: An abnormally rapid heart rate, which may feel like heart palpitations.
• Gastrointestinal Issues: Nausea, vomiting, constipation, or upper abdominal pain.
• Dizziness and Lightheadedness: Often occurring when standing up quickly (orthostatic hypotension).
• Upper Respiratory Tract Infections: Symptoms similar to a common cold, including cough or nasal congestion.
• Hyperprolactinemia: Elevated levels of the hormone prolactin, which can lead to breast enlargement (gynecomastia), nipple discharge, or menstrual irregularities.

• Priapism: A prolonged, painful erection that lasts for more than 4 hours, which is a medical emergency.
• Seizures: Lowering of the seizure threshold can occur, particularly in patients with a history of epilepsy.
• Severe Allergic Reactions: Anaphylaxis or angioedema (swelling of the face, lips, or throat).
• Agranulocytosis: A dangerous drop in white blood cell counts, making the body highly susceptible to infection.

> Warning: Stop taking Paliperidone Palmitate and call your doctor immediately if you experience any of these.

• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction characterized by high fever, stiff muscles, confusion, sweating, and changes in pulse or blood pressure.
• Tardive Dyskinesia (TD): A serious condition involving uncontrollable, repetitive muscle movements, usually in the face, tongue, or jaw. This may become permanent even if the drug is stopped.
• Hyperglycemia (High Blood Sugar): Symptoms include extreme thirst, frequent urination, and fruity-smelling breath. In severe cases, this can lead to ketoacidosis or coma.
• QT Prolongation: An alteration in the heart's electrical activity that can lead to dangerous arrhythmias (irregular heartbeats).
• Dysphagia: Difficulty swallowing, which can lead to aspiration pneumonia (food or liquid entering the lungs).

Prolonged use of paliperidone palmitate requires ongoing monitoring for metabolic changes. Long-term effects may include:

• Metabolic Syndrome: A cluster of conditions including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels, which increase the risk of heart disease and stroke.
• Bone Density Loss: Chronic hyperprolactinemia may lead to decreased bone mineral density, increasing the risk of fractures.
• Persistent Tardive Dyskinesia: The risk of developing TD increases with the duration of treatment and the total cumulative dose.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis:

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Paliperidone palmitate is NOT approved for the treatment of patients with dementia-related psychosis.

Report any unusual symptoms to your healthcare provider. Regular blood tests and physical exams are necessary to monitor for these effects.

Paliperidone palmitate is a potent medication that requires careful clinical supervision. Patients and caregivers must be aware that this medication remains in the body for several months after the last injection. Therefore, any side effects or adverse reactions may persist long after the drug is discontinued. It is vital to maintain all scheduled appointments for monitoring and to report any new or worsening symptoms to a healthcare provider immediately.

As mandated by the FDA, paliperidone palmitate carries a prominent 'Black Box Warning' regarding its use in elderly patients. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone palmitate is not approved for the treatment of dementia-related psychosis. Physicians must evaluate the risks and benefits of antipsychotic use in elderly populations with extreme caution, particularly those with a history of cardiovascular disease or infections.

• Cerebrovascular Adverse Reactions: In clinical trials of elderly patients with dementia, there was a higher incidence of stroke and transient ischemic attacks (TIAs), some of which were fatal. This further reinforces why the drug is not indicated for dementia-related psychosis.
• Neuroleptic Malignant Syndrome (NMS): This is a potentially fatal symptom complex. Clinical manifestations include hyperpyrexia (high fever), muscle rigidity, altered mental status, and evidence of autonomic instability. Management should include immediate discontinuation of the drug and intensive symptomatic treatment.
• QT Prolongation: Paliperidone can cause a modest increase in the corrected QT (QTc) interval on an EKG. It should be avoided in combination with other drugs known to prolong the QTc interval or in patients with congenital long QT syndrome.
• Orthostatic Hypotension and Syncope: Due to its alpha-adrenergic blocking activity, paliperidone may induce low blood pressure, especially during the initial dose-titration period. Patients with known cardiovascular or cerebrovascular disease are at higher risk.
• Leukopenia, Neutropenia, and Agranulocytosis: Patients with a history of a clinically significant low white blood cell (WBC) count or drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy.

Healthcare providers will typically require the following tests to ensure safety:

• Blood Glucose: To monitor for the development of diabetes or worsening of pre-existing diabetes.
• Lipid Panel: To check for increases in cholesterol and triglycerides.
• Weight: Regular monitoring of body weight is essential due to the risk of significant weight gain.
• Prolactin Levels: If symptoms of hyperprolactinemia appear (e.g., menstrual changes, breast discharge).
• CBC: Regular blood counts if there is a history of low white blood cell levels.

Paliperidone palmitate may impair judgment, thinking, or motor skills. Since somnolence (drowsiness) and dizziness are common side effects, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that paliperidone therapy does not affect them adversely.

Patients should be advised to avoid alcohol while taking paliperidone palmitate. Alcohol can exacerbate the sedative effects of the medication, leading to extreme drowsiness, respiratory depression, and an increased risk of falls or accidents.

Because paliperidone palmitate is a long-acting injection, it cannot be 'stopped' quickly. If a decision is made to discontinue treatment, the medication will gradually leave the system over several months. Patients should never attempt to miss a scheduled injection without consulting their doctor, as this can lead to a rapid return of psychotic symptoms (withdrawal emergence). Tapering is usually managed by extending the interval between injections or transitioning back to oral medications under strict supervision.

> Important: Discuss all your medical conditions, including any heart rhythm problems or history of low white blood cell counts, with your healthcare provider before starting Paliperidone Palmitate.

While there are few absolute contraindications for drug combinations with paliperidone, certain drugs should be avoided due to severe risks:

• Strong CYP3A4 and P-gp Inducers (e.g., Rifampin): These can significantly decrease the plasma concentration of paliperidone, rendering the treatment ineffective. If a strong inducer is necessary, the healthcare provider may need to increase the paliperidone dose or switch to a different therapy.
• Drugs that Prolong the QT Interval: Medications such as thioridazine, quinidine, or certain moxifloxacin antibiotics should not be used with paliperidone, as the combination significantly increases the risk of life-threatening heart arrhythmias (Torsades de Pointes).

• Dopamine Agonists (e.g., Levodopa, Bromocriptine): Paliperidone is a dopamine antagonist, meaning it blocks dopamine receptors. Taking it with dopamine agonists used for Parkinson’s disease can cause both medications to fail, worsening Parkinson's symptoms and psychiatric symptoms simultaneously.
• Centrally Acting Drugs: Caution should be used when paliperidone is taken in combination with other centrally acting drugs (e.g., opioids, benzodiazepines, or sleep medications) due to the additive risk of profound sedation and respiratory depression.
• Antihypertensive Medications: Because paliperidone can cause orthostatic hypotension, it may enhance the effects of blood pressure-lowering drugs, leading to dangerously low blood pressure and fainting.

• Lithium: While often used together for schizoaffective disorder, the combination may increase the risk of extrapyramidal symptoms or neurotoxicity. Close monitoring for neurological side effects is required.
• Valproate: Studies show that co-administration of oral paliperidone with valproate increases the peak concentration and area under the curve (AUC) of paliperidone by approximately 50%. Dose adjustments may be necessary if valproate is added or removed from the regimen.

For the injectable form of paliperidone palmitate, there are no specific food restrictions. Unlike the oral extended-release tablets (Invega), which must be taken with or without food consistently, the absorption of the palmitate ester from the muscle is not influenced by the contents of the stomach. However, patients should maintain a healthy diet to manage potential weight gain and metabolic changes associated with the drug.

• St. John’s Wort: This herbal supplement is a known inducer of metabolic enzymes and may reduce the levels of paliperidone in the blood, potentially leading to a relapse of symptoms.
• Kava Kava / Valerian Root: These supplements have sedative properties and can increase the drowsiness caused by paliperidone, increasing the risk of falls.
• CBD/Cannabis: May interact with the psychiatric effects of the medication and increase the risk of sedation or cognitive impairment.

Paliperidone palmitate does not typically interfere with common laboratory tests, but it can cause physiological changes that reflect in lab results:

• Prolactin Tests: Will likely show elevated levels.
• Blood Glucose/A1c: May show elevations indicating hyperglycemia.
• Cholesterol/Triglycerides: May show increases in lipid levels.

For each major interaction, the mechanism often involves either pharmacodynamic competition (blocking the same receptors) or pharmacokinetic changes (altering how the body processes the drug). Management strategies usually involve dose titration, frequent monitoring of vital signs, or selecting alternative medications that do not share the same side effect profile.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines and sleep aids.

Paliperidone palmitate must NEVER be used in the following circumstances:

• Known Hypersensitivity: Patients with a known hypersensitivity to paliperidone, risperidone (the parent compound), or any of the excipients (inactive ingredients) in the injection should not receive this medication. Hypersensitivity reactions can range from mild rashes to severe anaphylaxis (a life-threatening allergic reaction involving difficulty breathing and swelling).
• Severe Renal Impairment (for specific formulations): In patients with a creatinine clearance (CrCl) of less than 50 mL/min, the use of the 3-month (Invega Trinza) and 6-month (Invega Hafyera) formulations is contraindicated because the dose cannot be adjusted finely enough to ensure safety. For the monthly formulation (Invega Sustenna), use is not recommended for those with CrCl < 50 mL/min.

Conditions requiring a careful risk-benefit analysis by a healthcare professional include:

• History of Seizures: Paliperidone can lower the seizure threshold. It should be used with caution in patients with a history of epilepsy or conditions that lower the seizure threshold (e.g., brain injury).
• Cardiovascular Disease: Patients with a history of heart failure, recent myocardial infarction (heart attack), or conduction abnormalities (like QT prolongation) require close monitoring, as the drug can affect heart rhythm and blood pressure.
• Parkinson’s Disease or Lewy Body Dementia: These patients are at a significantly increased risk of Neuroleptic Malignant Syndrome and extreme sensitivity to antipsychotic medications, which can lead to severe extrapyramidal symptoms or falls.
• Conditions Predisposing to Hypotension: Such as dehydration or hypovolemia (low blood volume), which can increase the risk of fainting when taking the drug.

Because paliperidone is the active metabolite of risperidone, there is a high likelihood of cross-sensitivity. If a patient has had a severe allergic reaction to Risperdal (risperidone), they must not be given paliperidone palmitate. Healthcare providers will typically perform a trial with oral paliperidone or risperidone before administering the long-acting injection to ensure the patient tolerates the compound.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to antipsychotic medications, before prescribing Paliperidone Palmitate.

According to the FDA, paliperidone palmitate is classified under a system where its use in pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus.

• Neonatal Risks: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. These symptoms may include agitation, hypertonia (stiffness), hypotonia (floppiness), tremor, somnolence, respiratory distress, and feeding disorder.
• Teratogenicity: Animal studies have shown some evidence of fetal risk at high doses, but adequate and well-controlled studies in pregnant women are lacking. There is a pregnancy exposure registry that monitors outcomes in women exposed to atypical antipsychotics.

Paliperidone is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants (such as sedation or muscle movement issues), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. The long-acting nature of the injection means the drug will be present in milk for months after the last dose.

Safety and effectiveness of paliperidone palmitate in patients under 18 years of age have not been established for schizoaffective disorder. For schizophrenia, while oral paliperidone is approved for adolescents (ages 12-17), the injectable forms are generally reserved for adults due to the complexity of dosing and the lack of long-term safety data in developing children. Long-term effects on growth and sexual maturation (due to prolactin elevation) are significant concerns in this population.

Clinical studies of paliperidone palmitate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, geriatric patients are at a higher risk for:

• Falls: Due to sedation and orthostatic hypotension.
• Dementia-Related Death: As noted in the Black Box Warning.
• Renal Decline: Since the drug is cleared by the kidneys, elderly patients often require lower doses and frequent monitoring of renal function.

Renal function must be assessed before starting paliperidone palmitate.

• Mild Impairment (CrCl 50-80 mL/min): Doses must be reduced. The initiation doses and maintenance doses are typically lowered by approximately 25-30%.
• Moderate to Severe Impairment (CrCl < 50 mL/min): The use of long-acting injections is generally not recommended because the fixed-dose nature of the injection does not allow for the significant dose reductions needed to prevent toxicity.

In patients with mild to moderate hepatic impairment, no dosage adjustment is required. Paliperidone is not significantly metabolized by the liver. However, it has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), so it should be used with caution in this group.

> Important: Special populations require individualized medical assessment and frequent follow-up to ensure the safety of both the patient and, in the case of pregnancy, the developing child.

Paliperidone palmitate is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Its therapeutic mechanism is primarily attributed to its high-affinity antagonism of central dopamine D2 and serotonin 5-HT2A receptors. By blocking D2 receptors in the mesolimbic pathway, it reduces the positive symptoms of psychosis. Simultaneously, its antagonism of 5-HT2A receptors in the prefrontal cortex is thought to modulate dopamine release and improve negative symptoms while reducing the risk of extrapyramidal side effects compared to first-generation antipsychotics.

Additionally, paliperidone acts as an antagonist at alpha-1 and alpha-2 adrenergic receptors and H1 histaminergic receptors. It does not have an affinity for muscarinic or beta-adrenergic receptors. The drug's action at these various receptors explains its broad clinical profile, including its sedative and hypotensive side effects.

Paliperidone is the major active metabolite of risperidone. The pharmacodynamic activity of paliperidone palmitate is identical to that of oral paliperidone. It produces a dose-dependent increase in prolactin levels due to its D2 antagonism in the tuberoinfundibular pathway. The onset of action for the injectable form is gradual; while some receptor binding occurs within 24 hours, full therapeutic effects for schizophrenia symptoms may take several weeks to stabilize as plasma levels reach a steady state.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intramuscular) |

| Protein Binding | ~74% (Albumin and alpha1-acid glycoprotein) |

| Half-life | 25–49 days (Monthly formulation) |

| Tmax | ~13 days (Monthly formulation) |

| Metabolism | Minimal (Not primarily CYP450 dependent) |

| Excretion | Renal 80%, Fecal 11% |

• Molecular Formula: C39H49FN4O4
• Molecular Weight: 656.8 g/mol
• Solubility: Practically insoluble in water; sparingly soluble in 0.1 N HCl; soluble in ethanol.
• Structure: It is the palmitate ester of paliperidone (9-hydroxyrisperidone). The long fatty acid chain (palmitate) makes the molecule highly lipophilic, which is the basis for its slow-release properties when injected into muscle tissue.

Paliperidone palmitate is classified as an atypical antipsychotic (second-generation). It is part of the benzisoxazole class, which also includes its parent drug, risperidone. Compared to other atypical antipsychotics like olanzapine or quetiapine, paliperidone is unique in its heavy reliance on renal excretion and its availability in ultra-long-acting injectable formulations.